Bifogade filer
PR EN CEO Resigns 250923
Kurs
-3,72%
Likviditet
0,62 MSEK
Prenumeration
Kalender
| Est. tid* | ||
| 2026-02-20 | 08:00 | Bokslutskommuniké 2025 |
| 2025-11-21 | 08:00 | Kvartalsrapport 2025-Q3 |
| 2025-08-28 | - | Kvartalsrapport 2025-Q2 |
| 2025-05-27 | - | X-dag ordinarie utdelning NOVKAN 0.00 SEK |
| 2025-05-26 | - | Årsstämma |
| 2025-05-23 | - | Kvartalsrapport 2025-Q1 |
| 2025-02-21 | - | Bokslutskommuniké 2024 |
| 2024-11-15 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-23 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-28 | - | X-dag ordinarie utdelning NOVKAN 0.00 SEK |
| 2024-05-27 | - | Extra Bolagsstämma 2024 |
| 2024-05-27 | - | Årsstämma |
| 2024-05-17 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-23 | - | Bokslutskommuniké 2023 |
| 2023-11-17 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-18 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-26 | - | X-dag ordinarie utdelning NOVKAN 0.00 SEK |
| 2023-05-25 | - | Årsstämma |
| 2023-05-19 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-21 | - | Bokslutskommuniké 2022 |
| 2022-10-26 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-19 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-27 | - | X-dag ordinarie utdelning NOVKAN 0.00 SEK |
| 2022-05-25 | - | Årsstämma |
| 2022-05-20 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-18 | - | Bokslutskommuniké 2021 |
| 2021-11-19 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-20 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-27 | - | X-dag ordinarie utdelning NOVKAN 0.00 SEK |
| 2021-05-26 | - | Årsstämma |
| 2021-05-21 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-24 | - | Split NOVKAN 10:1 |
| 2021-02-19 | - | Bokslutskommuniké 2020 |
| 2020-11-20 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-21 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-29 | - | X-dag ordinarie utdelning NOVKAN 0.00 SEK |
| 2020-05-28 | - | Årsstämma |
| 2020-05-22 | - | Kvartalsrapport 2020-Q1 |
| 2020-04-09 | - | Extra Bolagsstämma 2020 |
| 2020-02-21 | - | Bokslutskommuniké 2019 |
| 2020-01-31 | - | Extra Bolagsstämma 2019 |
| 2020-01-13 | - | Extra Bolagsstämma 2019 |
| 2019-11-22 | - | Kvartalsrapport 2019-Q3 |
| 2019-05-28 | - | X-dag ordinarie utdelning NOVKAN 0.00 SEK |
| 2019-05-27 | - | Årsstämma |
| 2019-05-24 | - | Kvartalsrapport 2019-Q1 |
| 2019-05-23 | - | Kvartalsrapport 2019-Q2 |
| 2019-02-22 | - | Bokslutskommuniké 2018 |
| 2018-11-23 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-24 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-31 | - | X-dag ordinarie utdelning NOVKAN 0.00 SEK |
| 2018-05-30 | - | Årsstämma |
| 2018-05-28 | - | Kvartalsrapport 2018-Q1 |
| 2018-04-20 | - | Extra Bolagsstämma 2018 |
| 2018-02-20 | - | Bokslutskommuniké 2017 |
| 2017-11-17 | - | Kvartalsrapport 2017-Q3 |
| 2017-09-28 | - | Extra Bolagsstämma 2017 |
| 2017-08-22 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-31 | - | X-dag ordinarie utdelning NOVKAN 0.00 SEK |
| 2017-05-30 | - | Årsstämma |
| 2017-05-19 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-21 | - | Bokslutskommuniké 2016 |
| 2016-11-18 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-19 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-29 | - | X-dag ordinarie utdelning NOVKAN 0.00 SEK |
| 2016-05-26 | - | Årsstämma |
| 2016-05-03 | - | Kvartalsrapport 2016-Q1 |
| 2016-04-22 | - | Extra Bolagsstämma 2016 |
| 2016-02-19 | - | Bokslutskommuniké 2015 |
| 2015-11-20 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-21 | - | Kvartalsrapport 2015-Q2 |
| 2015-05-29 | - | X-dag ordinarie utdelning NOVKAN 0.00 SEK |
| 2015-05-28 | - | Årsstämma |
| 2015-05-22 | - | Kvartalsrapport 2015-Q1 |
| 2015-02-20 | - | Bokslutskommuniké 2014 |
| 2014-11-21 | - | Kvartalsrapport 2014-Q3 |
| 2014-08-22 | - | Kvartalsrapport 2014-Q2 |
| 2014-05-27 | - | X-dag ordinarie utdelning NOVKAN 0.00 SEK |
| 2014-05-26 | - | Årsstämma |
| 2014-05-23 | - | Kvartalsrapport 2014-Q1 |
| 2014-02-22 | - | Bokslutskommuniké 2013 |
| 2013-11-08 | - | Kvartalsrapport 2013-Q3 |
| 2013-10-30 | - | Extra Bolagsstämma 2013 |
| 2013-08-23 | - | Kvartalsrapport 2013-Q2 |
| 2013-05-29 | - | X-dag ordinarie utdelning NOVKAN 0.00 SEK |
| 2013-05-28 | - | Årsstämma |
| 2013-05-24 | - | Kvartalsrapport 2013-Q1 |
| 2013-02-22 | - | Bokslutskommuniké 2012 |
| 2012-11-22 | - | Kvartalsrapport 2012-Q3 |
| 2012-08-23 | - | Kvartalsrapport 2012-Q2 |
| 2012-05-29 | - | X-dag ordinarie utdelning NOVKAN 0.00 SEK |
| 2012-05-28 | - | Årsstämma |
| 2012-05-24 | - | Kvartalsrapport 2012-Q1 |
| 2012-02-23 | - | Bokslutskommuniké 2011 |
| 2011-11-24 | - | Kvartalsrapport 2011-Q3 |
| 2011-11-10 | - | Extra Bolagsstämma 2011 |
| 2011-08-31 | - | Kvartalsrapport 2011-Q2 |
| 2011-05-30 | - | X-dag ordinarie utdelning NOVKAN 0.00 SEK |
| 2011-05-27 | - | Årsstämma |
| 2011-05-24 | - | Kvartalsrapport 2011-Q1 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Novakand Pharma AB (publ) today announces that CEO Peter Selin has decided to resign as CEO of the company. The decision is made in mutual agreement with the Board of Directors. Peter Selin will remain available to the company for six months, or until a successor has taken office.
The decision follows Novakand Pharma's, formerly Kancera AB, recently announced direction to initiate a process to identify stakeholders for a reverse take over. Peter Selin has a profile that is suited to lead companies with a focus on clinical development and commercialization of pharmaceuticals. As the company is now discontinuing this business and instead focusing on finding stakeholders for other types of business, it is a natural time for Peter to hand over to a new CEO with expertise suitable for the company’s new direction.
Peter Selin will remain in the role of CEO and will continue to work within the company during a transition period of six months. During this time, he will support the Board of Directors in the process of identifying stakeholders for a reverse take over and in the process of divesting the company's clinical assets.
About Novakand Pharma AB
Novakand Pharma is a clinical stage biotech developing a new class of small molecule drugs with an immune cell modulating mode-of-action. The stock is traded on the Nasdaq First North Premier Growth Market (up until September 23, 2025 the share is traded under the trade name Kancera AB). Redeye AB is the company’s Certified Adviser and can be contacted at certifiedadviser@redeye.se.
For further information:
Contact: ir@novakand.com or +46 (0)8-5012 60 80.
This information is information that Kancera is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-09-23 15:00 CEST.